Shattuck Labs, Inc. (NASDAQ:STTK) CEO Taylor Schreiber Purchases 36,500 Shares

Shattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) CEO Taylor Schreiber acquired 36,500 shares of the business's stock in a transaction dated Monday, October 7th. The shares were bought at an average price of $1.21 per share, for a total transaction of $44,165.00. Following the acquisition, the chief executive officer now owns 71,002 shares of the company's stock, valued at approximately $85,912.42. This represents a 100.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shattuck Labs Trading Up 11.5 %

Shattuck Labs stock traded up $0.13 during mid-day trading on Tuesday, hitting $1.26. The company had a trading volume of 1,663,329 shares, compared to its average volume of 448,981. Shattuck Labs, Inc. has a 12-month low of $1.07 and a 12-month high of $11.76. The company's fifty day moving average is $3.30 and its 200-day moving average is $5.85. The company has a market capitalization of $59.91 million, a price-to-earnings ratio of -0.68 and a beta of 1.72.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.01). Shattuck Labs had a negative return on equity of 68.65% and a negative net margin of 2,067.99%. The company had revenue of $1.61 million during the quarter, compared to analysts' expectations of $0.50 million. The business's revenue was up 704.5% on a year-over-year basis. As a group, sell-side analysts expect that Shattuck Labs, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Shattuck Labs

Hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company purchased a new position in shares of Shattuck Labs during the 2nd quarter valued at approximately $67,000. Renaissance Technologies LLC lifted its position in shares of Shattuck Labs by 83.1% during the 2nd quarter. Renaissance Technologies LLC now owns 392,010 shares of the company's stock valued at $1,513,000 after buying an additional 177,910 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Shattuck Labs by 8.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 69,062 shares of the company's stock valued at $266,000 after buying an additional 5,397 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Shattuck Labs by 25.4% during the 2nd quarter. American Century Companies Inc. now owns 47,367 shares of the company's stock valued at $183,000 after buying an additional 9,608 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new position in Shattuck Labs in the 2nd quarter valued at $170,000. Hedge funds and other institutional investors own 58.74% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. BTIG Research downgraded shares of Shattuck Labs from a "buy" rating to a "neutral" rating in a report on Monday, June 17th. HC Wainwright downgraded shares of Shattuck Labs from a "buy" rating to a "neutral" rating in a report on Tuesday, October 1st. Evercore ISI upgraded shares of Shattuck Labs to a "strong-buy" rating in a report on Wednesday, October 2nd. Citigroup downgraded shares of Shattuck Labs from a "buy" rating to a "neutral" rating and cut their price target for the stock from $8.00 to $2.00 in a report on Wednesday, October 2nd. Finally, Needham & Company LLC downgraded shares of Shattuck Labs from a "buy" rating to a "hold" rating and set a $8.00 price target on the stock. in a report on Wednesday, October 2nd. Four investment analysts have rated the stock with a hold rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $8.67.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.